Sonnet biotherapeutics reports fiscal year 2024 financial results and provides corporate update

Continued progress with both clinical trials of lead program, son-1010, for solid tumors and platinum-resistant ovarian cancer (proc)
SONN Ratings Summary
SONN Quant Ranking